Oral or Parenteral Methotrexate for the Treatment of Polyarticular Juvenile Idiopathic Arthritis

Abstract

Objective: Subcutaneous methotrexate injections are considered to be more effective or work faster than oral methotrexate. Therefore, the extent and the kinetics of response were analyzed in juvenile idiopathic arthritis patients treated with oral versus subcutaneous methotrexate. Methods: The BIKER databank was searched for biologics-naive juvenile idiopathic arthritis patients treated with methotrexate as initial treatment. The Juvenile Arthritis Disease Activity Score-10 definition of remission and the pediatric American College of Rheumatology's response parameters were utilized as outcome criteria. Result: A total of 410 polyarticular juvenile idiopathic arthritis patients receiving oral methotrexate were compared to 384 patients receiving subcutaneous methotrexate. Rheumatoid factor-negative polyarthritis was the most common juvenile idiopathic arthritis category (50%/51%) in this cohort followed by extended oligoarthritis (27%/26%), polyarticular psoriatic arthritis (18%/16%), and few had rheumatoid factor-positive polyarthritis (5%/8%). The oral cohort’s disease duration (2.3 ± 3.0 vs. 1.9 ± 2.7) was significantly longer ( P = .04), although their age at onset and baseline were similar. Furthermore, at baseline, disease activity (Juvenile Arthritis Disease Activity Score-10 16.5 ± 7.2 vs. 14.7 ± 8.2; P = .001 due to a higher active joint count 9.0 ± 10.1 vs. 7.4 ± 7.7; P = .011) was higher in the subcutaneous cohort. The weekly methotrexate doses were comparable with 13.6 ± 5.4 mg/m 2 and 13.3 ± 4.5 mg/m 2 , respectively. With oral/subcutaneous methotrexate, a pediatric American College of Rheumatology’s 90 was achieved in 98(38.3%)/128(40.4%), while 96(38.1 %)/75(40.1%) attained Juvenile Arthritis Disease Activity Score remission after 12 months of therapy. There was no difference in the early kinetics of response according to Kaplan–Meyer analysis. Adverse events including nausea, vomiting, and increased transaminases were considerably more common after methotrexate subcutaneous administration than after oral treatment. Conclusion: In terms of effectiveness, but not safety, our retrospective analysis found some advantages of subcutaneous methotrexate. Adverse effects limit treatment continuance and thus must be considered a disadvantage. Furthermore, oral methotrexate eliminates the need for injections, which is especially essential for younger children. Controlled, randomized prospective trials in children and juvenile patients are necessary for definitive recommendations for the subcutaneous route of administration of methotrexate therapy.

A Comparison Between Enteral and Parenteral Methotrexate Intake in Iraqi Patients With Rheumatoid Arthritis Regarding Efficacy and Liver Function Impairment

“…The current study showed that parenteral MTX is more efficacious in getting a low disease activity (as shown in Table 4, the CDAI score significantly decreased from 13.15±3.25 to 5.57±2.34), whereas oral MTX causes an insignificant reduction in CDAI score from 12.72±3.13 to 8.90±3.08. This result is similar to studies by Bakry et al, and Choonhakarn et al [13,14]. While a study by Heuvelmans et al had some arguments about the efficacy of oral MTX and concluded that tends to be not inferior to the parenteral one, especially when the dose approaches 25 mg weekly [15].…”

Adherence to low-dose methotrexate in children with juvenile idiopathic arthritis using a sensitive methotrexate assay

“…On the other hand, this could reflect a cohort that was relatively tolerable of MTX with less risk of non-adherence issues. MTX intolerance develops mostly within the first year of use and none of the patients in our cohort were tapering MTX or switched the route of administration (as coping mechanism of intolerance) [ 8 , 13 ]. According to our protocols, JIA patient take MTX as long as it is effective as monotherapy in an as high as tolerable dose.…”